Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,338 |
Ending reported balance
After 2026-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 298,338 Row 2 · 2026-03-18 · Grant · Acquired 4,000 · Balance 302,338 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.93 | $221.85 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,698 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 29, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.66 | $254.70 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,653 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 28, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.68 | $255.60 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,608 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 27, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.27 | $237.15 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,563 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 23, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.14 | $231.30 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,518 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 22, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.10 | $229.50 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,473 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 21, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.05 | $227.25 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,428 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 20, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.41 | $243.45 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,383 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 19, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.92 | $221.40 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,338 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 16, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.37 | $241.65 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,293 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 15, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.20 | $234.00 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,248 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 14, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.68 | $255.60 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,203 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 13, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.67 | $255.15 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,158 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 12, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $5.25 | $236.25 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,113 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 09, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.78 | $215.10 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,068 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 08, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.50 | $202.50 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,023 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 07, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.71 | $211.95 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,978 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 06, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.60 | $207.00 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,933 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 05, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.68 | $210.60 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,888 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 02, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.75 | $213.75 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,843 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| May 01, 2025 Filed Jun 6, 2025 12:39 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.86 | $218.70 |
DisclosureSEC source: 0001628280-25-029856 · wk-form4_1749213581.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,798 F1 · shares: The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 30, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.79 | $215.55 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,753 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 29, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.93 | $221.85 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,708 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 28, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.91 | $220.95 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,663 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 25, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.94 | $271.70 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,618 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 24, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $5.12 | $281.60 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,563 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 23, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $5.01 | $275.55 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,508 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 22, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.74 | $260.70 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,453 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 21, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.79 | $263.45 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,398 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 17, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.61 | $253.55 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,343 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 16, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.23 | $232.65 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,288 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 15, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.14 | $227.70 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,233 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 14, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 55 | $4.03 | $221.65 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,178 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 11, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.02 | $180.90 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,123 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 10, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.01 | $180.45 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,078 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.09 | $184.05 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,033 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 08, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.14 | $186.30 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,988 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 07, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.19 | $188.55 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,943 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 04, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.23 | $190.35 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,898 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 03, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.21 | $189.45 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,853 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 02, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.39 | $197.55 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,808 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| April 01, 2025 Filed May 9, 2025 21:02 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.24 | $190.80 |
DisclosureSEC source: 0001628280-25-024346 · wk-form4_1746824546.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,763 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 31, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.29 | $193.05 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,718 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 28, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.20 | $189.00 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,673 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 27, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.20 | $189.00 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,628 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 26, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.41 | $198.45 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,583 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 25, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.45 | $200.25 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,538 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 24, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 45 | $4.42 | $198.90 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,493 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 21, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $4.89 | $180.93 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,448 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 20, 2025 Filed Apr 4, 2025 17:36 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 37 | $5.07 | $187.59 |
DisclosureSEC source: 0001628280-25-016741 · wk-form4_1743788198.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,411 F1 · shares: The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.